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ABSTRACT
Introduction: Only 30–40% of depressed patients
treated with medication achieve full remission. Studies
that change medication or augment it by
psychotherapy achieve only limited benefits, in part
because current treatments are not designed for
chronic and complex patients. Previous trials have
excluded high-risk patients and those with comorbid
personality disorder. Radically Open Dialectical
Behaviour Therapy (RO-DBT) is a novel,
transdiagnostic treatment for disorders of emotional
over-control. The REFRAMED trial aims to evaluate the
effectiveness and cost-effectiveness of RO-DBT for
patients with treatment-resistant depression.
Methods and analysis: REFRAMED is a multicentre
randomised controlled trial, comparing 7 months of
individual and group RO-DBT treatment with treatment
as usual (TAU). Our primary outcome measure is
depressive symptoms 12 months after randomisation.
We shall estimate the cost-effectiveness of RO-DBT by
cost per quality-adjusted life year. Causal analyses will
explore the mechanisms by which RO-DBT is effective.
Ethics and dissemination: The National Research
Ethics Service (NRES) Committee South Central –
Southampton A first granted ethical approval on
20 June 2011, reference number 11/SC/0146.
Trial registration number: ISRCTN85784627.
INTRODUCTION
The WHO predicts that by 2020 depression
will be the second most frequent cause of
disability worldwide.1 In the UK, the esti-
mated treatment cost of mood disorders was
£25 billion in 2006, some 1.5% of gross
domestic product (GDP).2 Although there
are efﬁcacious treatments for depression,
only half of these individuals respond to psy-
chological treatment and only 30–40% of
individuals treated with antidepressants
achieve full remission.3 Treatment resistance
is a common outcome for individuals with
depression,3 and those with chronic depres-
sion are least likely to respond to current
available treatments.4 Treatment-resistant depres-
sion (TRD) is depression that does not
respond to adequate intervention, whereas
chronic depression is depression lasting more
than 2 years. In practice, chronic depression
and TRD overlap, with many patients
meeting both deﬁnitions. The term refractory
depression (RD) encapsulates both deﬁnitions.
Research on intervention for RD is sparse,
and most have focused on pharmacological or
somatic methods. A recent systematic review of
trials of medication for TRD reported many
conceptual and methodological problems
relating to consensus on deﬁning and
Strengths and limitations of this study
▪ This study tests a novel and promising psycho-
therapeutic intervention, specifically designed for
patients with chronic depression that is hard to
treat.
▪ Radically Open Dialectical Behaviour Therapy
(RO-DBT) is manualised, and is increasingly
used for over-controlled patients.
▪ Our inclusive sample will add general findings to
the limited evidence base on interventions for
refractory depression.
▪ Our mechanistic analyses will estimate the role
of mediators, including therapeutic alliance and
adherence to treatment, by reducing bias inher-
ent in conventional analyses of mediation.
▪ Our comparator for the effectiveness of RO-DBT
is usual clinical practice, including medication
and other psychotherapies.
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assessing RD, or on adequate response to treatment.3
Another review identiﬁed only four trials of psychothera-
peutic treatment for TRD, none of which recruited more
than 25 participants.5 Most such trials also exclude the
most severely disturbed individuals, for example, those
with comorbid personality disorder (PD) who are known
to respond less favourably to existing treatments for acute
depression, notably cognitive behavioral therapy.4
Few psychotherapy trials focus on patients with RD
because current treatments may not be designed to
meet their needs. One exception is Cognitive Behavioral
Analysis System of Psychotherapy (CBASP) which was
developed speciﬁcally to respond to chronic depres-
sion.6 In one trial, depressed individuals who did not
respond to nefazodone, an antidepressant and were ran-
domised to receive CBASP had a better response rate
than those who continued to receive nefazodone only.7
However, a recent large trial showed when an individua-
lised regimen of antidepressants was augmented by
either CBASP or brief supportive psychotherapy (BSP)
in partial or non-responders, neither psychotherapy
added signiﬁcant beneﬁt to medication; only 38%
derived clinically signiﬁcant improvement from further
medication or psychotherapy.8 This study reﬂects earlier
ﬁndings from the Sequenced Treatment Alternatives to
Relieve Depression study (STAR*D) which found that,
among patients who failed to respond to antidepressant
medication (ADM), fewer than one-third beneﬁted from
adding or switching to, cognitive therapy.9 10 Finally,
although the Re-ChORD trial showed that a package of
group interpersonal psychotherapy, medication and
occupational therapy achieved better remission rates
than treatment as usual (TAU) at the end of the treat-
ment trial, it lacked data to show that these gains were
maintained.11
This protocol outlines a randomised controlled trial of
Radically Open Dialectical Behaviour Therapy
(RO-DBT), a novel psychotherapeutic treatment for
RD.12 13 RO-DBT arises from neurobiosocial theory14
and the observation that current treatments neglect the
role of emotional over-control in RD. It proposes that,
although the ability to inhibit competing urges,
impulses, behaviours and desires is valued by most soci-
eties,15 too much self-control can be problematic.
Excessive self-control has been linked to social isolation,
aloof interpersonal functioning, maladaptive perfection-
ism, disingenuous emotional expression and mental
health problems like anorexia nervosa, obsessive-
compulsive PD and chronic depression.16–20 Of the uni-
polar depressed patients, 40–60% meet criteria for
comorbid PD;21–23 over-controlled PDs, notably para-
noid, avoidant and obsessive-compulsive, are the most
common and least likely to respond to treatment.4 21 24
Children exhibiting behavioural over-controlled traits
like shyness, timidity, restrained emotional expression
and risk aversion are more likely to develop internalising
disorders and become socially isolated adults.16 17 25 26
Adults with chronic depression are characterised by over-
controlled traits, including greater self-criticism,
impaired autonomy, rigid internalised expectations,
excessive control of spontaneous emotion and inordin-
ate fears of making mistakes.23
The neurobiosocial theory underlying RO-DBT posits
that individuals presenting with problems of over-control
are biologically predisposed to exhibit heightened threat
sensitivity, diminished reward sensitivity, strong tenden-
cies towards constraint and preoccupation with details.14
Heightened biotemperamental threat sensitivity predis-
poses a person to prioritise the potential for harm over the
potential for reward when entering new or unfamiliar
situations, thereby activating sympathetic nervous system
(SNS) defensive-arousal and ﬁght–ﬂight responses.
These perceptual biases are strengthened by family or
environmental histories reinforcing avoidance of risk
and masking of emotions. Heightened SNS arousal also
triggers withdrawal of social safety engagement
responses mediated by the parasympathetic nervous
system ventral vagal complex (PNS-VVC).27
Unfortunately, when the PNS-VVC is withdrawn and
SNS-mediated ﬂight–ﬁght responses dominate, neurore-
gulatory responses linked with prosocial engagement are
impaired, facial expressions become frozen and the
ability to express oneself ﬂexibly is lost.27 28 Inhibited or
incongruent expressions of emotion are perceived as
inauthentic or untrustworthy by others and thus
increases social ostracism.29 30 Since these responses may
create or maintain depressive symptoms, RO-DBT
uniquely emphasises both communicative and facilitative
functions of emotional expressions in the formation of
close social bonds and empathic behaviours via micromi-
micry and the mirror neuron system.12 13 31 Therapy
includes training patients to relax rigid inhibitory self-
control efforts, to activate the VVC-mediated social-safety
system, to use non-verbal social-signalling skills linked to
the mirror neuron system and the establishment of trust
to allow vulnerable self-disclosure, to practice self-
enquiry to learn from new experiences and critical feed-
back, and to reduce maladaptive social comparisons
related to envy and bitterness.
Earlier versions of RO-DBT showed promise in two
trials of patients with refractory depression and
comorbid PD.32 33 The manualised version of RO-DBT12
has also been effective in two open trials of adults with
anorexia nervosa.34 35
Objectives
Our primary aim is to estimate the effectiveness of
RO-DBT in treating RD, compared with TAU. We shall
also estimate the cost-effectiveness of RO-DBT relative to
TAU alone. We also plan to study moderators of treat-
ment effects and mechanisms of therapeutic change. As
RO-DBT emphasises the therapist’s role as a model of
interpersonal skills, we predict that the development
and maintenance of a strong therapeutic alliance will
mediate reductions in depressive symptoms. Similarly,
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since the treatment is challenging, we regard adherence
as an important potential mediator.
METHODS
Design and setting
REFRAMED is a multicentre, randomised controlled
trial conducted at three National Health Service (NHS)
sites in the UK—Dorset, Hampshire and North Wales.
These sites routinely offer outpatient psychological treat-
ment. All trial participants receive TAU, but those allo-
cated at random to the experimental arm also receive
7 months of RO-DBT. We also allocate participants at
random between non-therapeutic alternatives designed
to facilitate mediational analyses. We measure clinical
outcomes at four time points—baseline, and 7, 12 and
18 months after randomisation, using assessors blind to
participants’ allocated treatment.
Participants
Inclusion criteria
Participants must be 18 years or older, and have a
Hamilton-Depression Rating Scale (HAM-D)36 score of
at least 15, a current diagnosis of major depressive dis-
order in the Structured Clinical Interview for DSM-IV
Axis I (SCID-I),37 and either TRD deﬁned as two or more
previous episodes of depression or chronic depression.
In their current episode, furthermore, participants must
have taken an adequate dose of ADM for at least 6 weeks
without relief.
Exclusion criteria
We exclude those who meet criteria for dramatic–erratic
PD (Cluster B), bipolar depression or psychosis, or have
a primary diagnosis of substance dependence or sub-
stance abuse disorder. Patients must have an IQ of more
than 70 and speak English well enough to participate in
the research, including treatment.
Procedures
Please see ﬁgure 1 for a CONSORT diagram of the
REFRAMED study participant recruitment, assessment
and follow-up timeline.
Recruitment
We recruit participants through mental health clinicians,
general practitioners (GPs) and advertisements in clinics
and community. Clinical study ofﬁcers within local NHS
organisations handle enquiries and screen potential par-
ticipants for inclusion criteria and the absence of exclu-
sion criteria by telephone, using a standardised
checklist. If eligible and willing, participants attend a
second assessment interview.
Eligibility
Our team of trained assessors establish whether these
potential participants are indeed eligible. They also
administer the baseline assessment of the outcome
measures set out in table 1. After the interview, partici-
pants receive further questionnaires for home comple-
tion. Our assessment lead (HO) monitors interassessor
reliability, in particular whether κ’s for SCID and
HAM-D are consistently at least 0.70.
Randomisation
Once we receive all baseline questionnaires, we allocate
each participant between treatments through an adap-
tive randomisation algorithm administered by Swansea
Trials Unit. This maintains the balance across groups of
three stratifying variables chosen as potential outcome
moderators, but stochastically rather than deterministic-
ally to minimise risk of subversion:64
A. Early onset of depression, that is, before 21 years of
age
B. Depression severe at baseline (HAM-D above 25)
C. Personality disorder (meets SCID-II criteria for
cluster A or cluster C)
Figure 1 CONSORT diagram of REFRAMED study
participant recruitment, assessment and follow-up timeline.
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We also use adaptive randomisation to allocate patients
between therapists so as to use as many feasible treatment
slots at each centre. The allocation sequence was deter-
mined dynamically using a database independently admi-
nistered at the study’s Clinical Trials Unit; the database
incorporated a study-speciﬁc version of a published
dynamic randomisation allocation method,65 and the
resulting allocations were then sent by email to the Trial
Manager for further dissemination to study therapists.
Mediation and instrumental variables
To understand the mechanisms by which RO-DBT
improves outcomes, we shall conduct mediation analyses
to estimate the effects of postrandomisation measures
on the pathway from randomisation to outcome.
Conventional mediation analyses may be biased by unob-
served confounding, that is confounding by unobserved
variables related to both the mediators and the out-
comes.66 67 Confounding arises because, following ran-
domisation to treatment arm, patients choose the
manner in which they adhere to treatment and the level
of adherence; if one patient adheres in a certain way
and coincidentally suffers worse depression, confound-
ing ensues. To address unobserved confounding, we
shall use ‘instrumental variables’ (IVs) which:
1. Predict the likelihood that a patient will adhere to
treatment;
2. Are unrelated to the study outcome; and
3. Are unrelated to the unobserved confounding variables.
If we can ﬁnd one or more IVs, we can use methods
like two-stage least squares to estimate the unconfounded
effect of the mediator. The biggest challenge is to ﬁnd
IVs. Some occur naturally; for example, genes can serve
as IVs: one variant of the ALDH2 gene makes it unpleas-
ant for individuals to drink alcohol, facilitating unbiased
estimates of the effect of alcohol on health from observa-
tional data.68 Alternatively, researchers make additional
random allocations between options that are not thera-
peutic in their own right, but may inﬂuence mediators;69
for example, enhancing the therapeutic environment
may enhance alliance (the mediator), but have no direct
effect on symptoms (the outcome).
REFRAMED has adopted both approaches to facilitate
bias-corrected estimates of the effects of two hypothe-
sised mediators: strength of therapeutic alliance and adher-
ence to treatment. We randomly allocate all RO-DBT
participants to one of eight combinations of contextual
non-therapeutic features within a 2×2×2 factorial design:
A. They receive individual RO-DBT in either a standard
therapy room or an enhanced therapy room, which
Table 1 Assessment schedule and overview of measures
Measurement occasion
Baseline Treatment Follow-up
Month 0 1 2 3 4 5 6 7 8 9 10 11 12 18
Primary outcomes
Depression (HAM-D, LIFE-RIFT) • • • •
Health-related quality of life (EQ-5D-3 L) • • • • •
Health services use/costs (AD-SUS) • • • •
Secondary outcomes
Suicide (MSSI, SBQ) • • • •
Depression and affect (PHQ-9, PANAS) • • • • • • • • • • • • • •
Mechanisms and mediators
Psychosocial function(WBSI, SSQ3, IIP-PD-25, DBT-WCCL) • • • • •
Emotional approach and expectancy (EAC, CEQ) • • • • • • • • • • • • • •
Alliance and delivery of treatment (CALPAS, CSQ-8,
sessions attended)
• • • • • • • •
Moderators of RO-DBT effectiveness
Personality and personality disorder (SCID-I and II,
NEO-FFI-C, applied conscientiousness task, SVS)
•
Temperament and emotional control (UPPS, PNS,
Ego-undercontrol, Ego-resiliency, BIDR-SF, FMPS)
•
Childhood experience and invalidation (ICES, MOPS) •
AAQ-II, Acceptance and Action Questionnaire-II;38 AD-SUS, Adult Service Use Schedule;39 AEQ, Ambivalence over Emotional expression
Questionnaire;40 BIDR-SF, Balanced Inventory of Desirable Responding-Short Form (Hart CM, Ritchie T, Hepper EG, et al The Balanced
Inventory of Desirable Responding Short Form: Reliability, validity and factor structure. submitted manuscript 2012);CALPAS, California
Psychotherapy Alliance Scales;41 CEQ, Credibility/Expectancy Questionnaire;42 CSQ-8, Client Satisfaction Questionnaire–8;43 DBT-WCCL,
Dialectical Behavior Therapy Ways of Coping Checklist;44 EAC, Emotional Approach Coping scale;45 EQ-5D-3L, European Quality of Life
Questionnaire—5 Dimensions;46 FMPS, Frost Multidimensional Perfectionism Scale;47 HAM-D, Hamilton Rating Scale for Depression;36
ICES, Invalidating Childhood Experiences Scale;48 IIP-PD-25, Inventory of Interpersonal Problems-Personality Disorders-25 items;49
LIFE-RIFT, the Longitudinal Interval Follow-up Evaluation—Range of Impaired Functioning Tool;50 MOPS, Measure of Parenting Style;51
MSSI, Modified Scale for Suicide Ideation;52 NEO-FFI, NEO Five Factor Inventory;53 PANAS, Positive and Negative Affect Scale;54 PHQ-9,
Patient Health Questionnaire-9;55 PNS, Personal Need for Structure;56 SBQ, Suicidal Behaviors Questionnaire;57 SCID-I and SCID-II,
Structured Clinical Interviews for DSM-IV;37 58 SCS, Self-Compassion Scale;59 SSQ3, Social Support Questionnaire;60 SVS, Schwartz Values
Scale;61 UPPS, Urgency Premeditation Perseverance Sensation Seeking scale;62 WBSI, White Bear Suppression Inventory.63
4 Lynch TR, et al. BMJ Open 2015;5:e008857. doi:10.1136/bmjopen-2015-008857
Open Access
potentially improves both strength of therapeutic alli-
ance and attendance at treatment;
B. After every session they either have or do not have
opportunity to provide written feedback to their therapist,
which improves strength of therapeutic alliance;70
and
C. They receive compensation potentially for question-
naire completion either personally (via their thera-
pists) or impersonally (via mail), again potentially
increasing attendance at treatment.
While we recognise that these ploys may have limited
inﬂuence on our adopted mediators,71 we include them
both for their potential to reduce bias in our estimates,
and to encourage the wider adoption and discussion of
these methods in psychotherapy research.
Intervention phase (29 weeks)
Treatment as usual
This control intervention permits participants to receive
any psychotherapy or prescribed (ADM) with the excep-
tion of standard DBT. We monitor type and amount of
psychotherapy, and type of ADM and adherence to it.
Reporting these data will better describe this generic
intervention. In particular, we do not restrict access to
appropriate mental healthcare during follow-up.
Radically open-dialectical behavior therapy
This experimental intervention comprises 29 weekly
individual therapy sessions lasting 50–60 min, and 27
weekly skills training classes lasting 2.5 h, including a
15 min break (table 2). RO-DBT therapists meet weekly
for 1.5–2.5 h, and by telephone when needed.12 13
While RO-DBT participants receive ADM as prescribed,
we strongly discourage them from seeking additional
psychotherapy during RO-DBT. The RO-DBT treatment
developer and study chief investigator (TRL) does not
contribute to the treatment.
Therapist training and supervision
All therapists had to complete a two-part, 10-day
RO-DBT intensive training course over 6 months and
additional training or supervision when needed to
achieve adherence to the treatment manual. We video-
tape all treatment sessions and shall sample 10% of both
therapy sessions and skills classes at random, stratiﬁed by
therapist and participant, for adherence rating.
Discontinuations
If participants are unable or unwilling to attend RO-DBT
sessions, we consider them as treatment drop-outs but
encourage them to provide outcome data. If they with-
draw from data collection, we permit them to continue
with RO-DBT. If they withdraw consent to participate in
the study, however, we do not seek further data.
Outcome measures
Table 1 summarises the schedule of outcome measures.
Primary outcome
The primary outcome is depressive symptoms, measured
on the 17-item Hamilton Rating Scale for Depression
(HAM-D)36 at four points (baseline, and 7, 12 and
18 months after randomisation) by assessors who report
their ‘blindness’ after each assessment. We replace them
with unblinded assessors for subsequent assessments.
Secondary outcomes
Secondary outcomes at the same four points include
remission status, and suicidal ideation and behaviour.
We deﬁne remission as the combination of a HAM-D
score of less than 8 and minimal functional impairment
on the Longitudinal Interval Follow-up Evaluation—
Range of Impaired Functioning Tool (LIFE-RIFT);50 we
measure suicidal thoughts and behaviours on the
Modiﬁed Scale for Suicidal Ideation52 and the Suicidal
Behaviors Questionnaire.57
Health economics data
We collect health economic data alongside our primary
outcomes. For health costs we use the Adult Service Use
Schedule (AD-SUS); and for health utility the European
Quality of Life Questionnaire (EQ-5D-3 L).46 The
AD-SUS measures medication and service use, and lost
productivity due to illness, in mental health populations,
including patients with depression.39 We also ask thera-
pists about unscheduled time in treating RO-DBT
patients, notably calls out of hours.
Mediators of outcome
We collect data on potential outcome mediators
throughout the treatment and follow-up using question-
naires to measure interpersonal, emotional, and psycho-
social functioning, strength of therapeutic alliance, use
of skills taught in treatment and expectancy (table 1).
Between these questionnaires, we collect data on
mood, emotional coping and the credibility of and
expectancy attached to the intervention, once a month
for the ﬁrst 12 months and again at 18 months. We also
use an automated telephone system to measure mood
(PANAS Short-Form),72 coping skills (6 items from the
DBT-WCCL)44 and self-compassion (Self-Compassion
Scale)59 once a week over the ﬁrst 6 months that partici-
pants are in the trial.
Moderating variables
At baseline we collect data on potential moderating vari-
ables, including basic demographics and Axis I and Axis
II disorders, childhood experiences and invalidation,
and personality and markers of personality disorder
(table 1). To control for social desirability, we ask partici-
pants to complete the Balanced Inventory of Desirable
Responding-Short Form. (Hart CM, Ritchie T, Hepper
EG, et al. The Balanced Inventory of Desirable
Responding Short Form: Reliability, validity, and factor
structure. submitted manuscript 2012).
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Characteristics of therapists
To investigate whether therapist characteristics, and their
relationship with patient characteristics inﬂuence
outcome, we collect measures of perfectionism (Frost
Multidimensional Perfectionism Scale),47 personal
values (Schwartz Values Scale)61 and attachment experi-
ences (Measure of Parenting Style).51 To provide an
instrumental variable for strength of therapeutic alli-
ance, we measured therapists’ capacity to generate
strong alliances before the trial by asking several patients
from the caseload of each therapist to complete the
California Therapeutic Alliance Scale.41
Sample size estimation
Based on an average effect sizes close to one from two
RO-DBT pilot trials for RD32 33 and one pilot trial of
DBT for TRD,73 we judged it feasible and desirable to
power REFRAMED to detect a standardised difference
of 0.4 between-groups (RO-DBT and TAU)—likely to be
considered clinically relevant by the UK National
Institute of Health and Care Excellence (NICE).
In the absence of intraclass correlation, a sample of
200 analysable participants from the three centres would
yield 80% power when using a signiﬁcance level of 5%
to detect a mean difference of two points on the
HAM-D, equivalent to a standardised difference of 0.4.
Since we expect to collect analysable data from 83% of
participants, we increased our initial target to 240. To
increase the power of our mechanistic analyses, we
planned to randomise 144 of these to RO-DBT. As parti-
cipants receiving RO-DBT are clustered by therapist, we
increased the target RO-DBT sample size from 144 to
180 to allow for an intracluster correlation coefﬁcient of
0.025 for HAM-D scores, and an average cluster size of
11. Thus we aim to randomise 276 patients—180 to
RO-DBT and 96 to TAU (a ﬁnal allocation ratio of 15:8).
Statistical analyses
For our primary measure of depression (HAM-D), we
shall analyse by treatment allocated and use a
mixed-effects model to estimate the effectiveness of
RO-DBT. This will include random effects to account for
clustering of outcomes by therapist, and ﬁxed effects to
Table 2 RO-DBT treatment goals and target hierarchy for over-controlled disorders
Primary targets and goals
DECREASE severe behavioural over-control, emotional loneliness and aloofness/distance
INCREASE openness, flexibility, prosocial signalling and vulnerable expression of emotion
Treatment target hierarchy for over-control
1. Life-threatening
behaviours
Suicidal ideation and non-suicidal self-injury
Over-controlled self-injurious behaviour tends to be planned in advance, occurs in private and
rarely requires immediate medical attention
2. Therapeutic alliance
ruptures
Patient feels misunderstood or perceives therapy as not relevant to their problems
Signals of non-engagement by over-controlled patients tend to be understated, for example
saying “hmm”, “maybe” or “I guess so” when disagreeing, or by avoiding eye contact or changing
the topic when feeling misunderstood
3. Over-controlled
Behavioural themes
Constrained expressions of emotion
Over-controlled patients tend to display inhibited, flattened or insincere facial expressions (eg,
smiling when distressed, showing concern when not feeling it), have a monotonic voice tone and
tight and non-expansive gestures or body movements. They will work hard to avoid public
displays of emotion
Overly cautious and hyper-vigilant
Over-controlled patients are not necessarily avoidant but guarded, wary and suspicious. They
exhibit superior detailed-focused processing
Rigid and rule-governed behaviours
The actions of over-controlled patients tend to be non-mood dependent and instead follow
certain self-imposed rules. They are motivated by social obligation and exhibit high moral
certitude; they often make self-sacrifices to care for others or to do the ‘right’ thing. They tend to
be hyper-perfectionistic and have compulsive needs for order and structure
Aloof and distant relationships
Over-controlled patients do not necessarily lack contact but lack social connectedness with
others. They are slow to warm-up and will walk away or abandon a relationship when in conflict.
They are likely to feel like an outsider, different or detached from others
Envy, Resentment, Bitterness and Revenge
Over-controlled patients tend to be performance-focused, engage in social comparisons, are
secretly competitive, tend to hold grudges and may have secret pride in superior capacities for
self-control. They may take pleasure in a rival failing or feel unappreciated for personal
self-sacrifices or efforts on their part to meet or exceed expectations
Targets higher in the treatment hierarchy take priority over lower ones. Thus, life-threatening behaviors and therapeutic alliance-ruptures take
precedence over behavioral themes when these are present. Therapists use the behavioral themes to facilitate treatment planning.
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account for treatment allocation, differences between
sites and their interaction. In particular, this model does
not assume that all therapists are equally effective.74
Covariates will include baseline HAM-D score, diagnosis
of PD at baseline and age at ﬁrst onset of depression.
Repeated HAM-D measurements enable us to compare
RO-DBT and TAU at 7, 12 and 18 months after random-
isation. Secondary analyses will test for interaction
between treatment allocation and covariates, and esti-
mate the marginal effect of RO-DBT within strata. If
data are missing at random (MAR), these models will be
unbiased and efﬁcient. We shall, therefore, analyse
missing data thoroughly and qualify our conclusions
accordingly.
Mechanisms, instrumental variables and causal analyses
Initially our causal analysis will consider each potential
mediator in turn, estimating both the direct effect of
treatment via exposure, and the indirect effect via the
mediator. Following Baron and Kenny,75 we shall
compare the resulting estimates with those from a naïve
analysis that assumes no unobserved confounding, and
state the assumptions under which the causal estimates
are unbiased and consistent. Finally we shall extend
these analyses to a joint model of all mediators and IVs.
To explore patterns of temporal ordering from skill
acquisition, through development of the therapeutic alli-
ance, to changes in depressive symptoms, we shall use
multivariate growth curve models including autoregres-
sive and lagged terms.
Economic evaluation
We shall undertake cost-utility analysis to estimate the
cost effectiveness of RO-DBT relative to TAU alone in
terms of cost per Quality-Adjusted Life Year (QALY)
derived from the EQ-5D-3L. We shall use cost-
effectiveness analysis of depressive symptoms from the
HAM-D as sensitivity analysis. Our primary perspective
will be that of the NHS and personal social services, as
preferred by the National Institute for Health and Care
Excellence (NICE).76 Again we shall consider societal
losses due to lost productivity, including both absence
from work and reduced productivity during work, in the
sensitivity analysis. We shall estimate cost-effectiveness
through both approaches used to estimate clinical effect-
iveness: conventional analysis by treatment allocated,
and IV analysis based on treatment received, that is
adherence. We shall use non-parametric bootstrapping
to generate the joint distribution of mean incremental
costs and effects of RO-DBT relative to TAU and thus,
explore the probability that one treatment is better,
given NICE’s ‘willingness-to-pay’ threshold of £20 000 to
£30 000 per QALY. We shall summarise uncertainty
around these estimates by cost-effectiveness acceptability
curves.77
Data collection and management
Paper data
To ensure accuracy, completeness and reliability, trained
assessors collect outcome data during interviews in
person or by phone by following standard operating pro-
cedures for data collection and transfer to the trial
ofﬁce in Southampton. Each month we post additional
paper questionnaires direct to participants with a free
return envelope, and send text or email reminders after
10 days.
Electronic data capture system
We enter all paper data twice onto Signalbox (http://
www.thesignalbox.net), a validated electronic data
capture system. This system also collects the data from
automated phone calls and therapists’ treatment notes
online, notably by issuing weekly electronic reminders.
Study monitoring
The Trial Steering Committee (TSC) and Data
Monitoring Committee (DMC) monitor the trial to
ensure we comply with the rigorous standards deﬁned in
the Medical Research Council’s (MRC) Guidelines for
Good Clinical Practice. The TSC meets twice a year
throughout the trial. The DMC met twice in the ﬁrst
year and annually since then. Both the TSC and DMEC
are independent from the Funder and Sponsor.
Reporting of adverse events and study termination
Site principal investigators (PIs) monitor and assess
serious adverse events (SAEs) and report them to the
chief investigator immediately, and to the DMC regu-
larly, or immediately when the SAE is a Suspected
Unexpected Serious Adverse Reaction (SUSAR). Site PIs
discuss SAEs with the relevant participants and their GPs
with their permission. The trial will terminate if the
TSC, on the recommendation of the DMC or the chief
investigator, judges it necessary for the welfare of trial
participants or for the scientiﬁc validity of the trial.
Ethical considerations and dissemination
We ask trial participants to give consent on three
occasions:
1. Oral consent to the phone screen;
2. Signed consent for the baseline assessment, stating
that they have read and understood the information
sheet and giving permission for the interview to be
audio recorded;
3. Eligible participants sign the reverse of their consent
forms, stating that they understand the patient infor-
mation sheet and are willing to participate in the
trial.
Personal information will kept on secure databases
(one for each site), only accessible to members of staff
who need these details for making assessment appoint-
ments and sending letters. These are the only ﬁles that
link personal information with the participant identiﬁca-
tion numbers.
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We conduct REFRAMED in accordance with the
Declaration of Helsinki. We have received approval from
the Hampshire Research Ethics Committee (National
Research Ethics Service (NRES) reference number 11/
SC/0146) and the Ethics & Research Governance
Department of the University of Southampton, the
Sponsor. REFRAMED has insurance cover under the
Sponsor’s Professional Indemnity and Clinical Trials
policy. All investigators comply with REFRAMED’s policy
on conﬂicts of interest, and will report conﬂicts of inter-
est in all resulting publications.
We shall implement and report REFRAMED in accord-
ance with all relevant CONSORT guidance. We plan to
publish the ﬁndings in high-impact, peer-reviewed jour-
nals and disseminate them to service providers and users
across the UK and beyond via public forums and web-
sites. In accordance with Research Council guidelines,
we shall store anonymised individual patient data from
REFRAMED in a repository accessible by other research-
ers following publication.
DISCUSSION
REFRAMED is a randomised controlled trial of a prom-
ising treatment for refractory depression with implica-
tions for other diagnoses. It will contribute to the
clinical literature in three ways:
1. Our broad selection criteria include patients rou-
tinely excluded from depression trials, namely those
with comorbid personality disorder, suicidal behav-
iour, non-suicidal self-injury, prior psychotherapy, fre-
quent relapse or older age. Hence the evidence base
is weak for these patients in most need of effective
treatment. Our inclusion criteria may mean that this
trial will have a higher rate of reported suicide
attempts than trials that exclude patients with PDs,
comorbid disorders and suicidal ideation. However,
our use of open criteria reﬂects the growing recogni-
tion that symptoms of many mental health conditions
may share a common aetiology, and that to exclude
patients with comorbidities signiﬁcantly undermines
the generalisability and utility of clinical trials.
2. RO-DBT offers a major change in approach to the
treatment of refractory depression. Most important is
a novel focus on behavioural over-control as a core
aetiological factor. The treatment proposes a new
mechanism of therapeutic change by linking neuore-
gulatory theory and the communicative functions of emo-
tional expression to the formation of close social bonds.
This translates into novel skills focused on social sig-
nalling and changing psychophysiological arousal—a
key component differentiating RO-DBT from other
treatments.
3. REFRAMED is the ﬁrst mental health trial to use
instrumental variables to analyse causes of mediation.
In particular, we have randomised RO-DBT partici-
pants between eight combinations of three context-
ual features that are not intended to be therapeutic
in their own right, but may affect mediating variables,
including strength of therapeutic alliance and adher-
ence to the treatment. This approach will yield esti-
mates of the effects of mediating variables that are
less biased by confounding than conventional esti-
mates. Thus it has the potential to resolve a long-
standing criticism of the literature that links strength
of therapeutic alliance with outcome—that patients
most likely to recover are those most able to form
strong alliances.
Design implications and limitations
REFRAMED does not use an active comparator. Instead,
patients in the control arm may access any type of treat-
ment available through the NHS or private healthcare.
NICE guidelines suggest combined approaches like
ADM and CBT for moderate to severe depression or
depression not responding to ﬁrst-line treatments.76
However, ADM alone is more readily available and often
preferred for those with unresponsive depression.8
Moreover, there is little evidence whether augmenting
ADM with psychotherapy is more or less effective than
switching between ADMs. Indeed NICE recommenda-
tions stem from one multisite study designed to
compare switching and augmentation following poor
response to acute ADM treatment, but whose ﬁndings
do not justify ﬁrm recommendations.
Current progress
REFRAMED has recruited participants from March 2012
until May 2015, and will complete data collection by
June 2016. All trial therapists have achieved good adher-
ence to the manual. During the pilot phase, the leading
site in Dorset achieved three other critical targets by:
recruiting 20 participants over 6 months; ensuring that
70% of these responded in full to the primary outcome;
and showing that they were satisﬁed with treatment
according to the Client Satisfaction Questionnaire–8.43
These achievements enabled the TSC to approve the
trial in full.
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